Recombinant Interleukin-19 Suppresses the Formation and Progression of Experimental Abdominal Aortic Aneurysms.
Hiroki Tanaka,Baohui Xu,Haojun Xuan,Yingbin Ge,Yan Wang,Yankui Li,Wei Wang,Jia Guo,Sihai Zhao,Keith J. Glover,Xiaoya Zheng,Shuai Liu,Kazunori Inuzuka,Naoki Fujimura,Yuko Furusho,Toru Ikezoe,Takahiro Shoji,Lixin Wang,Weiguo Fu,Jianhua Huang,Naoki Unno,Ronald L. Dalman
DOI: https://doi.org/10.1161/jaha.121.022207
IF: 6.106
2021-08-31
Journal of the American Heart Association
Abstract:Background Interleukin‐19 is an immunosuppressive cytokine produced by immune and nonimmune cells, but its role in abdominal aortic aneurysm (AAA) pathogenesis is not known. This study aimed to investigate interleukin‐19 expression in, and influences on, the formation and progression of experimental AAAs. Methods and Results Human specimens were obtained at aneurysm repair surgery or from transplant donors. Experimental AAAs were created in 10‐ to 12‐week‐old male mice via intra‐aortic elastase infusion. Influence and potential mechanisms of interleukin‐19 treatment on AAAs were assessed via ultrasonography, histopathology, flow cytometry, and gene expression profiling. Immunohistochemistry revealed augmented interleukin‐19 expression in both human and experimental AAAs. In mice, interleukin‐19 treatment before AAA initiation via elastase infusion suppressed aneurysm formation and progression, with attenuation of medial elastin degradation, smooth‐muscle depletion, leukocyte infiltration, neoangiogenesis, and matrix metalloproteinase 2 and 9 expression. Initiation of interleukin‐19 treatment after AAA creation limited further aneurysmal degeneration. In additional experiments, interleukin‐19 treatment inhibited murine macrophage recruitment following intraperitoneal thioglycolate injection. In classically or alternatively activated macrophages in vitro, interleukin‐19 downregulated mRNA expression of inducible nitric oxide synthase, chemokine C‐C motif ligand 2, and metalloproteinases 2 and 9 without apparent effect on cytokine‐expressing helper or cytotoxic T‐cell differentiation, nor regulatory T cellularity, in the aneurysmal aorta or spleen of interleukin‐19–treated mice. Interleukin‐19 also suppressed AAAs created via angiotensin II infusion in hyperlipidemic mice. Conclusions Based on human evidence and experimental modeling observations, interleukin‐19 may influence the development and progression of AAAs. Nonstandard Abbreviations and Acronyms AAA abdominal aortic aneurysm BMDM bone marrow–derived macrophage CCL chemokine (C‐C motif) ligand Foxp3 Forkhead Box P3 MMP matrix metalloproteinase PPE porcine pancreatic elastase rIL recombinant interleukin SMC smooth‐muscle cell TGF transforming growth factor Treg regulatory T cell Clinical Perspective What Is New? Recombinant cytokine interleukin‐19 suppressed the formation and progression of experimental abdominal aortic aneurysms in 2 distinct and complementary mouse abdominal aortic aneurysm modeling systems. Abdominal aortic aneurysm suppression by interleukin‐19 was associated with attenuation of medial elastin and smooth‐muscle destruction, mural leukocyte infiltration and neoangiogenesis, matrix metalloproteinases, and chemokine C‐C motif ligand 2. What Are the Clinical Implications? Medical interventions based on recombinant interleukin‐19 or its derivative strategies may hold the translational relevance for clinical abdominal aortic aneurysm disease management. Abdominal aortic aneurysm (AAA) is a common, age‐related degenerative disease of the infrarenal aortic segment. Characteristic histopathologic features of advanced AAA disease include medial elastin and vascular smooth‐muscle cell (SMC) depletion, transmural inflammatory cell accumulation, and neoangiogenesis. Multiple lines of evidence suggest that inflammation is central to the initiation and progression of AAAs, 1 including a recent prospective study showing the positive association of aortic uptake of ultrasmall superparamagnetic iron oxide particles with AAA enlargement, the risk for surgical aneurysm repair, and aneurysm‐specific mortality. 2 Cytokines are biologically active small peptides, recognized by their cognate receptors on targeting cells, and involved -Abstract Truncated-
cardiac & cardiovascular systems